Exploring anti-cancer activities of epidermal growth factor-immobilized polymeric nanoparticles
Shota Yamamoto1, Chia-Jung Chang1, Masao Kamimura2
1Research Center for Macromolecules & Biomaterials, National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan.
Abstract:
Cytotoxic agents targeting the epidermal growth factor receptor (EGFR) exhibit significant potential for cancer therapy as EGFR is overexpressed in various cancers. As alternatives to conventional EGFR inhibitors (EGFRi), which exert side effects on non-cancer cells, EGF-immobilized gold nanoparticles exhibit selective cytotoxicity in EGFR-overexpressing cancer cells by locally enhancing EGFR activation and modulating signal transduction through a signal condensation mechanism. However, considering real therapeutic applications, it is important to confirm that the same principle can be applied to polymeric nanoparticles, which are more suitable carriers owing to their biodegradability and biocompatibility, remains unclear. Therefore, in this study, we aimed to investigate the anti-cancer activities of EGF-conjugates with two kinds of polymeric nanoparticles: polystyrene nanoparticles and polymeric micelles. Initial mechanistic studies on phosphorylation signaling and cholesterol depletion revealed that EGF-polystyrene nanoparticles exhibited cytotoxicity against human cervical adenocarcinoma HeLa cells via local enhancement of EGFR activity in membrane rafts. Moreover, EGF-polymeric micelles exerted selective anti-cancer effects against EGFRi-resistant MDA-MB468 refractory triple-negative breast cancer cells after optimization of particle size. These results suggest that the unique anti-cancer effects of EGF nanoparticles are not dependent on the carrier platform. Furthermore, EGF nanoparticles exhibited high cytotoxicity against cancer cells responding poorly to conventional EGFR-targeted anti-cancer drugs, showing potential for future medical applications.
Insights
Epidermal growth factor receptor (EGFR) targeted therapies show promise for cancer treatment. EGF-conjugated polymeric nanoparticles demonstrate selective cancer cell cytotoxicity, offering a potential alternative to conventional EGFR inhibitors.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Biology
Background:
- Epidermal growth factor receptor (EGFR) is overexpressed in many cancers, making it a target for cancer therapy.
- Conventional EGFR inhibitors (EGFRi) can cause side effects in non-cancer cells.
- EGF-immobilized gold nanoparticles show selective cytotoxicity in EGFR-overexpressing cancer cells.
Purpose of the Study:
- To investigate the anti-cancer activities of epidermal growth factor (EGF)-conjugated polymeric nanoparticles.
- To determine if the selective cytotoxicity mechanism of EGF nanoparticles is carrier-dependent.
- To explore the therapeutic potential of EGF nanoparticles against drug-resistant cancer cells.
Main Methods:
- Conjugation of EGF to polystyrene nanoparticles and polymeric micelles.
- Assessment of cytotoxicity in human cervical adenocarcinoma HeLa and MDA-MB468 cells.
- Mechanistic studies involving phosphorylation signaling and cholesterol depletion.
- Optimization of nanoparticle size for enhanced efficacy.
Main Results:
- EGF-polystyrene nanoparticles showed cytotoxicity against HeLa cells via enhanced EGFR activity in membrane rafts.
- Optimized EGF-polymeric micelles exhibited selective anti-cancer effects against EGFRi-resistant MDA-MB468 cells.
- The anti-cancer effects of EGF nanoparticles were independent of the carrier material.
Conclusions:
- The anti-cancer effects of EGF nanoparticles are not dependent on the carrier platform.
- EGF nanoparticles demonstrate selective cytotoxicity against EGFR-overexpressing cancer cells, including those resistant to conventional therapies.
- EGF nanoparticles hold potential for future cancer therapeutic applications, particularly for cancers unresponsive to current treatments.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:19Clinical Applications of Epidermal Stem Cells